Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising
Novo Nordisk, maker of Ozempic, has filed a lawsuit against rival pharmaceutical company Eli Lilly, alleging that its advertising for weight-loss drugs is misleading, intensifying competition in the rapidly growing anti-obesity medication market.
The Story
Analyzing sources…
Source Diversity
Source Diversity
Excellent (100/100)Sources
Ozempic-maker sues rival, accusing it of false advertising
Novo Nordisk, the maker of Wegovy and Ozempic, has launched legal action accusing its arch rival Eli Lilly of false advertising.
Read full article →Novo Nordisk accuses Eli Lilly of deceptive marketing in weight-loss fight
Danish group claims rival used outdated data to support claims that its products were more effective than Wegovy
Read full article →Ozempic maker Novo Nordisk sues US rival over ‘materially misleading’ ads
Danish pharma company says Eli Lilly using outdated trial data to make its weight-loss drugs appear more effective Ozempic maker Novo Nordisk said Tuesday it is suing arch US rival Eli Lilly over “false and materially misleading” adverts for its competing weight-loss and anti-diabetes treatments. The Danish pharmaceuticals heavyweight complained that the US group – which makes rival weight-loss treatments Zepbound and Mounjaro – “intentionally selected outdated studies” that compared Lilly’s ...
By Agence France-Presse in Copenhagen
Read full article →Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo asked the court to permanently stop Lilly from running the "deceptive" ads and require the drugmaker to issue corrective advertising.
Read full article →Ozempic maker sues US rival over ad campaign
Novo Nordisk has claimed that Eli Lilly is using bad data to compare the companies' weight-loss and diabetes products in its ads.
Read full article →Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications
The Danish company Novo says U.S.-based Lilly isn’t including the most up-to-date clinical information about its drugs.
By Jaimy Lee
Read full article →Two weight-loss drugmakers in legal battle over which is most effective in helping users shed pounds
Novo Nordisk claims Eli Lilly compared peak doses of Zepbound against outdated, lower doses of Wegovy to advertise a 50-pound weight loss versus 33 pounds
By Jasmine Fernández
Read full article →Novo Nordisk sues rival Eli Lilly over weight loss drug advertising
Read full article →Pharma heavyweights Novo Nordisk and Eli Lilly clash over anti-obesity drug ads
Novo Nordisk said Eli Lilly's ads uses outdated research and leave out important information, which could mislead consumers.
Read full article →GLP-1 Fight: Novo Sues Eli Lilly Over Nationwide "Deceptive Advertising" Campaign
GLP-1 Fight: Novo Sues Eli Lilly Over Nationwide "Deceptive Advertising" Campaign Novo Nordisk wrote in a press release that it is suing GLP-1 rival Eli Lilly in federal court in New Jersey, alleging nationwide "deceptive advertising" for Zepbound and Mounjaro. The company claims Lilly misleads consumers by comparing Lilly's highest doses with lower doses of Novo's Wegovy and Ozempic. Novo claims Lilly's Zepbound advertising campaign relies on outdated studies that exclude the 7...
By Tyler Durden
Read full article →
